Advertisement

Factors Influencing Local and Systemic Levels of Plasma Myeloperoxidase in ST-Segment Elevation Acute Myocardial Infarction

      Myeloperoxidase (MPO) is associated with risk in acute coronary syndromes. However, the precise role it plays in ST-elevation myocardial infarction (STEMI) remains unclear. In this study we tested the hypothesis that levels of MPO in plasma after a myocardial infarction are affected by its ability to bind to the endothelium and there is local release of the enzyme at the culprit lesion. We measured plasma MPO in systemic circulation and throughout the coronary circulation in patients with STEMI undergoing primary percutaneous coronary intervention (PCI). MPO levels at the femoral artery were higher (p <0.001) in patients with STEMI (n = 67, median 45 ng/ml, interquartile range 34 to 83) compared to control patients (n = 12, 25 ng/ml, 19 to 30) with chronic stable angina undergoing elective PCI. After administration of the anticoagulant bivalirudin in 13 patients with STEMI, plasma MPO was increased only at the culprit coronary artery lesion before PCI (178 ng/ml, 91 to 245) versus all other sites (femoral artery 86 ng/ml, 54 to 139, p = 0.019). Administration of heparin caused a marked increase of plasma MPO. Even so, it was still possible to detect an increase of plasma MPO at culprit lesion in patients with STEMI (n = 54, 171 ng/ml, 122 to 230) versus controls (n = 12, 136 ng/ml, 109 to 151, p <0.05) after heparin and before PCI. MPO levels were higher at the culprit lesion in patients with STEMI who presented early and in those with restricted flow (p <0.05). In conclusion, our results demonstrate that, in addition to a systemic increase of MPO in patients presenting early with STEMI, levels of this leukocyte enzyme are increased at the culprit coronary lesion before PCI.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Baldus S.
        • Rudolph V.
        • Roiss M.
        • Ito W.D.
        • Rudolph T.K.
        • Eiserich J.P.
        • Sydow K.
        • Lau D.
        • Szocs K.
        • Klinke A.
        • Kubala L.
        • Berglund L.
        • Schrepfer S.
        • Deuse T.
        • Haddad M.
        • Risius T.
        • Klemm H.
        • Reichenspurner H.C.
        • Meinertz T.
        • Heitzer T.
        Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase.
        Circulation. 2006; 113: 1871-1878
        • TIMI Study Group
        The Thrombolysis In Myocardial Infarction (TIMI) trial.
        N Engl J Med. 1985; 312: 932-936
        • Mocatta T.J.
        • Pilbrow A.P.
        • Cameron V.A.
        • Senthilmohan R.
        • Frampton C.M.
        • Richards A.M.
        • Winterbourn C.C.
        Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction.
        J Am Coll Cardiol. 2007; 49: 1993-2000
        • Böyum A.
        Isolation of mononuclear cells and granulocytes from human blood.
        Scand J Clin Lab Invest. 1968; 21: 77-89
        • Nauseef W.M.
        How human neutrophils kill and degrade microbes: an integrated view.
        Immunol Rev. 2007; 219: 88-102
        • Li G.
        • Keenan A.C.
        • Young J.C.
        • Hall M.J.
        • Pamuklar Z.
        • Ohman E.M.
        • Steinhubl S.R.
        • Smyth S.S.
        Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirudin on myeloperoxidase release from neutrophils.
        Arterioscler Thromb Vasc Biol. 2007; 27: 1850-1856
        • Naruko T.
        • Ueda M.
        • Haze K.
        • van der Wal A.C.
        • van der Loos C.M.
        • Itoh A.
        • Komatsu R.
        • Ikura Y.
        • Ogami M.
        • Shimada Y.
        • Ehara S.
        • Yoshiyama M.
        • Takeuchi K.
        • Yoshikawa J.
        • Becker A.E.
        Neutrophil infiltration of culprit lesions in acute coronary syndromes.
        Circulation. 2002; 106: 2894-2900
        • Buffon A.
        • Biasucci L.M.
        • Liuzzo G.
        • D'Onofrio G.
        • Crea F.
        • Maseri A.
        Widespread coronary inflammation in unstable angina.
        N Engl J Med. 2002; 347: 5-12
        • Dominguez-Rogriguez A.
        • Samimi-Fard S.
        • Abreu-Gonzalez P.
        • Garcia-Gonzalez M.J.
        • Kaski J.C.
        Prognostic value of admission myeloperoxidase levels in patients with ST-segment elevation myocardial infarction and cardiogenic shock.
        Am J Cardiol. 2008; 101: 1537-1540
        • Khan S.Q.
        • Kelly D.
        • Quinn P.
        • Davies J.E.
        • Ng L.L.
        Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction.
        Heart. 2007; 93: 826-831
        • Galijasevic S.
        • Saed G.M.
        • Hazen S.L.
        • Abu-Soud H.M.
        Myeloperoxidase metabolizes thiocyanate in a reaction driven by nitric oxide.
        Biochemistry. 2006; 45: 1255-1262
        • Eiserich J.P.
        • Baldus S.
        • Brennan M.L.
        • Ma W.
        • Zhang C.
        • Tousson A.
        • Castro L.
        • Lusis A.J.
        • Nauseef W.M.
        • White C.R.
        • Freeman B.A.
        Myeloperoxidase, a leukocyte-derived vascular NO oxidase.
        Science. 2002; 296: 2391-2394
        • Vita J.A.
        • Brennan M.-L.
        • Gokee N.
        • Mann S.A.
        • Goormastic M.
        • Shishebor M.H.
        • Penn M.S.
        • Keaney J.F.
        • Hazen S.L.
        Serum myeloperoxidase levels independently predict endothelial dysfunction in humans.
        Circulation. 2004; 110: 1134-1139
        • Baldus S.
        • Eiserich J.P.
        • Mani A.
        • Castro L.
        • Figueroa M.
        • Chumley P.
        • Ma W.
        • Tousson A.
        • White C.R.
        • Bullard D.C.
        • Brennan M.L.
        • Lusis A.J.
        • Moore K.P.
        • Freeman B.A.
        Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration.
        J Clin Invest. 2001; 108: 1759-1770
        • Hazen S.L.
        Myeloperoxidase and plaque vulnerability.
        Arterioscler Thromb Vasc Biol. 2004; 24: 1143-1146
        • Goldmann B.U.
        • Rudolph V.
        • Rudolph T.K.
        • Holle A.K.
        • Hillebrandt M.
        • Meinertz T.
        • Baldus S.
        Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction.
        Free Radic Biol Med. 2009; 47: 79-83
        • Griffin S.V.
        • Chapman P.T.
        • Lianos E.A.
        • Lockwood C.M.
        The inhibition of myeloperoxidase by ceruloplasmin can be reversed by anti-myeloperoxidase antibodies.
        Kidney Int. 1999; 55: 917-925
        • Zheng L.
        • Nukuna B.
        • Brennan M.L.
        • Sun M.
        • Goormastic M.
        • Settle M.
        • Schmitt D.
        • Fu X.
        • Thomson L.
        • Fox P.L.
        • Ischiropoulos H.
        • Smith J.D.
        • Kinter M.
        • Hazen S.L.
        Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.
        J Clin Invest. 2004; 114: 529-541
        • Aminian A.
        • Boudjeltia K.Z.
        • Babar S.
        • Van Antwerpen P.
        • Lefebvre P.
        • Crasset V.
        • Leone A.
        • Ducobu J.
        • Friart A.
        • Vanhaeverbeek M.
        Coronary stenting is associated with an acute increase in plasma myeloperoxidase in stable angina patients but not in patients with acute myocardial infarction.
        Eur J Intern Med. 2009; 20: 527-532